Michael Labarre becomes Chief Scientific Officer at Halozyme Therapeutics

His career in biotech drug discovery and development spans two decades

Halozyme Therapeutics, a biotechnology company developing novel oncology and drug-delivery therapies, has named Michael LaBarre as Chief Scientific Officer. He succeeds Dr Michael Shepard, who was appointed a Research Fellow for the company.

The move broadens LaBarre's responsibilities to include research and development of early pipeline assets, in addition to his role managing product development and Enhanze platform partnerships.

LaBarre's career includes more than 20 years of biotech drug discovery and development experience.

Prior to joining Halozyme in 2008, he was Vice President of Product Development at Paramount BioSciences; Director of analytical and protein biochemistry, discovery research at Biogen Idec; and Director analytical and formulation sciences, research and development at IDEC Pharmaceuticals.

You may also like

Regulatory

Halozyme announces first clinical dosing of Pfizer's rivipansel using Enhanze technology

First healthy subject dosed in Halozyme collaboration with Pfizer
Packaging

Innovating primary packaging for parenteral drugs: challenges and future directions

The new challenges brought about by the pandemic call for an increasingly scientific approach to the evolution of single packaging elements in order to anticipate the needs of new drug formulations and guarantee a more enhanced, measurable and stable level of performance
Regulatory

US Pharmacopeia details mass spectrometry guidelines to advance biologics impurity control

The new chapter aims to standardise the use of mass spectrometry-based analysis in the biopharmaceutical industry, which can be used to detect impurities in cell and gene therapies, antibodies and other biologics
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Hybrid interferons: developing a novel drug class

With many hurdles to overcome, establishing a new drug candidate is a long process — particularly if you are a smaller biotech company with limited resources. These challenges can be further amplified if the candidate being developed is of an entirely novel drug class
Packaging

How pharma packaging manufacturers role is evolving: the case of extractables testing

As the pharmaceutical industry continues to grow and evolve, extractables testing is a critical component of the pharmaceutical industry's efforts to prioritise quality and safety, ensuring one of the key functions pharma containers are designed for, says Anna Malori, Head of Product Management at Bormioli Pharma
Distribution

2BScientific expands its life science product supply service to Europe with new German facility

The facility in Munich will serve the European market with life science products, including in vitro diagnostic (IVD) reagents, buffers, biomaterials and antibodies
Manufacturing

Anton Paar expands Litesizer DIA Series with new models

Introducing affordable and advanced solutions for particle analysis
Subscribe now